"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
| Descriptor ID |
D007167
|
| MeSH Number(s) |
E02.095.465.425
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".
This graph shows the total number of publications written about "Immunotherapy" by people in this website by year, and whether "Immunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 1 | 1 | 2 |
| 1996 | 1 | 0 | 1 |
| 1998 | 0 | 3 | 3 |
| 1999 | 2 | 1 | 3 |
| 2000 | 3 | 2 | 5 |
| 2001 | 2 | 5 | 7 |
| 2002 | 2 | 3 | 5 |
| 2003 | 2 | 4 | 6 |
| 2004 | 5 | 8 | 13 |
| 2005 | 3 | 2 | 5 |
| 2006 | 4 | 2 | 6 |
| 2007 | 4 | 1 | 5 |
| 2008 | 7 | 6 | 13 |
| 2009 | 4 | 2 | 6 |
| 2010 | 7 | 5 | 12 |
| 2011 | 5 | 5 | 10 |
| 2012 | 8 | 7 | 15 |
| 2013 | 8 | 9 | 17 |
| 2014 | 9 | 9 | 18 |
| 2015 | 9 | 16 | 25 |
| 2016 | 20 | 2 | 22 |
| 2017 | 22 | 3 | 25 |
| 2018 | 31 | 14 | 45 |
| 2019 | 28 | 16 | 44 |
| 2020 | 19 | 25 | 44 |
| 2021 | 22 | 20 | 42 |
| 2022 | 2 | 30 | 32 |
| 2023 | 3 | 31 | 34 |
| 2024 | 17 | 22 | 39 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conference. Oncoimmunology. 2025 Dec; 14(1):2432726.
-
Targeting DTX2/UFD1-mediated FTO degradation to regulate antitumor immunity. Proc Natl Acad Sci U S A. 2024 Dec 17; 121(51):e2407910121.
-
Harnessing Antitumor Immunity in Ovarian Cancer. Cold Spring Harb Perspect Med. 2024 Dec 02; 14(12).
-
Diagnostic Challenges due to a Germline Missense MSH2 Variant in a Patient With Immunotherapy-Responsive Locally Advanced Rectal Adenocarcinoma. Cancer Rep (Hoboken). 2024 Dec; 7(12):e70037.
-
Breathing down resistance: Tackling hypoxia to overcome immunotherapy barriers in lung cancer. J Exp Med. 2025 Jan 06; 222(1).
-
Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events. J Immunother Cancer. 2024 Nov 14; 12(11).
-
Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity. Cancer Immunol Res. 2024 Nov 04; 12(11):1525-1541.
-
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024. J Natl Compr Canc Netw. 2024 Nov; 22(9):582-592.
-
Dendritic cell-intrinsic PTPN22 negatively regulates antitumor immunity and impacts anti-PD-L1 efficacy. J Immunother Cancer. 2024 Oct 26; 12(10).
-
The impact of demographics and socioeconomic status on the receipt of immunotherapy for stage III melanoma. Surg Oncol. 2024 Dec; 57:102156.